

PHoenix

Title: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

(PHoenix): A phase IV randomised trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies

Short title: PHoenix

Authors: Frances Varian^{1, 2}, Jennifer Dick¹, Christian Battersby,¹ Stefan Roman,² Jenna Ablott,² Lisa Watson,² Sarah Binmahfooz,¹ Hamza Zafar,^{1,2} Gerry Colgan,³ John Cannon,⁴ Jay Suntharalingam,⁵ Jim Lordan,⁶ Luke Howard,⁷ Colm McCabe,⁸ John Wort,⁹ Laura Price,⁹ Colin Church,¹⁰ Neil Hamilton,² Iain Armstrong,² Abdul Hameed,² Judith Hurdman,² Charlie Elliot,² Robin Condliffe,² Martin Wilkins,¹⁰ Alastair Webb,¹¹ David Adlam,¹² Ray L Benza,¹³ Kazem Rahimi,¹⁴ Mohadeseh Shojaei-Shahrokhbadi,¹⁵ Nan X Lin,¹⁵ James M. S. Wason,¹⁵ Alasdair McIntosh,¹⁶ Alex McConnachie,¹⁶ Jennifer T Middleton,^{1,2} AA Roger Thompson,^{1,2} David G Kiely,^{1,2} Mark Toshner,¹⁷ Alexander Rothman^{1,2}

Affiliations:

¹Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

²Sheffield Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

³Royal Free NHS Foundation Trust, London, UK

⁴Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK

⁵Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

⁶Newcastle Hospitals NHS Foundation Trust, Newcastle, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

PHoenix

⁷Imperial College Healthcare NHS Trust, London, UK

⁸Royal Brompton and Harefield, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁹NHS Greater Glasgow and Clyde, Glasgow, UK

¹⁰National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK

¹¹Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, UK

¹²Cardiovascular Research Unit of Leicester, Leicester, UK

¹³Mount Sinai Heart, Icahn school of medicine at Mount Sinai, New York, New York

¹⁴Deep Medicine, Nuffield Department of Women's and Reproductive Health, University of Oxford

¹⁵Biostatistics Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

¹⁶Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK

¹⁷Heart and Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK

Corresponding author: Alex Rothman

Address: IICD, The Medical School, Beech Hill Road, Sheffield, S10 2RX, United Kingdom

Email: a.rothman@sheffield.ac.uk

Telephone number:

Target journal: *Pulmonary Circulation*

PHoenix

Total number of manuscript pages: 24

Total number of tables/figures: 2/3

Word count for the body of the text: 3,852 (9,000 max)

Type of contribution: Original article

Keywords: Remote monitoring, targeted therapy, soluble guanylate-cyclase stimulator, oral prostacyclin-receptor agonist

PHoenix

Abstract

Approved therapies for pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. Patients identified as intermediate-low risk, according to a four-strata risk assessment model, with an inadequate response to dual therapy with a phosphodiesterase type-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended to either intensify oral therapy by adding a selective prostacyclin receptor (IP) agonist (selexipag), or switching from PDE5i to a soluble guanylate-cyclase stimulator (sGCS; riociguat). The clinical equipoise between these therapeutic choices provides opportunity for evaluation of individualised therapeutic effect. Traditionally, invasive/hospital-based investigations are required to comprehensively assess disease severity and demonstrate treatment benefit. Regulatory approved, minimally invasive monitors enable equivalent measurements to be obtained while patients are at home. In this 2x2 randomised crossover trial, patients with PAH established on guideline-recommended dual therapy and implanted with CardioMEMS™ (a wireless pulmonary artery sensor) and ConfirmRx™ (an insertable cardiac rhythm monitor), will receive ERA + sGCS, or PDEi + ERA + IP agonist. The study will evaluate clinical efficacy via established clinical investigations and remote monitoring technologies, with remote data relayed through regulatory approved online clinical portals. The primary aim will be establishing the change in right ventricular systolic volume measured by magnetic resonance imaging (MRI) from baseline to maximal tolerated dose with each therapy. Using data from MRI and other outcomes, including haemodynamics, physical activity, physiological measurements, quality of life, and side effect reporting, we will determine whether remote technology facilitates early evaluation of clinical efficacy, and investigate intra-patient efficacy of the two treatment approaches.

PHoenix

Lay Summary

This is a study to test if monitors placed in the lungs and the heart can help to choose the best medications for patients with a diagnosis of pulmonary arterial hypertension (PAH). PAH is a condition that results in high blood pressure in the blood vessels that supply the lungs. This study is for patients with PAH who are already taking two PAH medications (called dual therapy) but continue to have symptoms limiting their daily life and ability to exercise. There are two additional medications called selexipag and riociguat that may be prescribed when patients are not responding well to dual therapy; if selexipag is used, it is added to the existing dual therapy (Arm A), but if riociguat is used it replaces one of the drugs in the dual therapy (Arm B). It is not known which one of these treatment approaches is better. This 3-year study is called a crossover study design to look at responses of 40 individual patients to each of these two treatment approaches. Before starting the study treatment, patients will be implanted with monitoring devices. These approved devices will allow heart rate, pressure in the lungs, and other measures to be taken and seen by the clinical team from any location, without patients needing to attend hospital.

Patients will be randomly selected to either start Arm A or Arm B, as shown in **Figure 1**, before being swapped to the other treatment arm; there is no placebo. For example, for patients starting on Arm A, one of their medications (called phosphodiesterase type-5 inhibitor [PDE5i] e.g., sildenafil/tadalafil) will be stopped for a short time before riociguat is started. The dose of riociguat will gradually be increased to maximum dose and at 12 weeks they will have a magnetic resonance imaging (MRI) scan will measure treatment effect. The patient will then switch over to Arm B, where their PDE5i is restarted prior to treatment with selexipag. The MRI scan captures an image of the heart at the start and end of both Arm A and Arm B to look for improvements in the heart function with therapy. The study will also use patient-reported outcomes to record how patients feel and any side effects, blood tests related to heart health,

PHoenix

and exercise tests to look at exercise ability. Each patient will be in the study for a total of 6 months, following which ongoing treatment choice will be decided at the discretion of the clinical care team.

Body text:

Pulmonary arterial hypertension (PAH) represents a spectrum of disease that may be idiopathic or associated with genetic mutations, connective tissue disease, congenital heart disease, or drug/toxin exposure.¹ At a cellular level, disease is driven by remodelling and constriction of the small pulmonary arteries, which can lead to right-sided heart failure and premature death.² Currently available targeted therapies for this progressive disease mediate pulmonary vascular vasodilatation by acting on one of three pathways – the endothelin pathway via endothelin receptor antagonists (ERA), the nitric oxide (NO) pathway via phosphodiesterase type-5 inhibitors (PDE5i) or soluble guanylate cyclase stimulators (sGCS), or the prostacyclin pathways via prostacyclin analogues and prostacyclin receptor (IP) agonists.^{1,3} Despite the range of therapies available, drug choice is empirical and based on a hospital-based risk stratification that matches the number of vasodilator agents to disease severity.³

Approved therapies targeting the endothelin, NO or prostacyclin pathways have been shown to provide improvements in pulmonary vascular haemodynamics and 6-minute walk test (6MWT) in phase 2/3 studies.^{1,4-8} Evidence shows that time to clinical worsening is further improved in patients established on dual therapy with an ERA and a PDE5i, when compared with monotherapy with either agent.^{3,9} In line with European guidelines,³ for patients established on dual oral therapy (PDE5i/ERA) with an inadequate treatment response, NHS England's National Commissioning Policy permits addition of the selective IP

PHoenix

receptor agonist selexipag, or switching of PDE5i for the sGCS riociguat.^{10,11} There is clinical equipoise between these two approaches (i.e., triple therapy with selexipag + PDE5i + ERA and dual therapy with riociguat + ERA).

Selexipag, an IP receptor agonist, improves the time-to-clinical-worsening in patients on a range of background therapy regimens (including patients on no therapy [20.4%]; ERA or PDE5i monotherapy [47.1%]; and ERA/PDE5i dual therapy [32.5%]).⁵ However, data suggest that initiating triple therapy (PDE5i/ERA/IP receptor agonist) compared with dual therapy (PDE5i/ERA) in newly diagnosed treatment naïve patients offers no significant improvement in snapshot haemodynamic measurements or exercise capacity.¹² Additionally, switching PDE5i for another drug targeting the NO pathway (riociguat, a sGCS) improves disease severity as assessed by World Health Organization (WHO) functional class and 6MWT distance, and reduces clinical worsening events compared with continuing PDE5i therapy.² In all regulatory approval studies, significant side effects and therapeutic non-adherence were observed.^{2,5,7,13-18}

In clinical practice, response to therapy and/or assessment of disease progression is made by assessing pressure and flow during invasive right heart catheterisation, by monitoring the downstream effect on right heart structure and function, and by evaluating exercise capacity. European Society of Cardiology (ESC) guidelines recommend invasive assessment of cardiopulmonary haemodynamics for disease diagnosis, assessment of severity, and to inform treatment decisions (therapeutic change and transplant).³ Other recommended means of guiding treatment decisions include regular measurement of exercise capacity by 6MWT, disease-specific risk scoring, assessment of right heart strain by N-terminal pro-brain natriuretic peptide (NT-proBNP), and/or non-invasive imaging, with magnetic resonance imaging (MRI) acknowledged to be more accurate than echocardiography.³

PHoenix

The current established standard for phase 2 studies of PAH therapies include assessment of invasive haemodynamics and the 6MWT. However, recent studies have demonstrated that non-invasive endpoints, such as right ventricular ejection fraction (RVEF) and right ventricular stroke volume (RVSV) measured by MRI, are repeatable, and detect treatment change in a manner similar to invasive catheterisation and NTpro-BNP, thereby establishing MRI as a robust, objective, non-invasive assessment of treatment response in patients with PAH.^{19,20}

Despite these advances, there remains a need for invasive/hospital-based investigations to assess disease severity and demonstrate therapeutic benefit, and there are currently no means for early assessment of clinical efficacy in patients with PAH. This limits experimental medicine and drug development studies and prevents personalised medicine in clinical practice. Development of innovative approaches to monitor PAH outcomes is essential for a number of reasons including poor prognosis among patients with PAH, reduced quality of life, side effect profile of approved therapies, non-uniform drug response among patients, high cost of PAH-specific therapies (£5–120k/medication/patient/year), and emerging therapies with proven benefit in pre-clinical studies.^{10,19-22}

In patients with PAH, cardiopulmonary haemodynamics are closely associated with clinical outcomes,⁸ and are affected by both disease worsening and increase or withdrawal of therapy.^{23,24} The development of minimally invasive technology that provides remote, daily measurement of cardiopulmonary haemodynamic parameters and physical activity may provide more comprehensive coverage of the effects of treatment on patients' daily functioning, allowing insight into the intervening periods between scheduled hospital visits.²⁵ Remote monitoring may provide benefit to both patients and care teams by allowing remote monitoring of efficacy following a treatment change. This may permit a personalised management approach, with the care team able to optimise therapy remotely – balancing

PHoenix

therapeutic efficacy with side effects in each individual patient. Indeed, in patients with heart failure, remote, haemodynamic-guided therapy has been demonstrated to reduce heart failure hospitalisation,^{26,27} and these studies have led to regulatory approval of pulmonary artery pressure (PAP) monitors. Furthermore, studies of patients with PAH implanted with a PAP monitor and an insertable cardiac monitor (ICM) demonstrated that clinically indicated therapeutic changes altered physiological parameters associated with mortality, indicating that early, remote assessment of clinical efficacy may be achieved using these devices.²⁸

CardioMEMS™ HF System (Abbott) is a wireless, CE-marked PAP monitor implanted at the time of right heart catheterisation to provide remote measurement of cardiopulmonary haemodynamics. CardioMEMS is approved for routine clinical practice in the USA and Europe, and to date over 30,000 of these monitors have been implanted. The Confirm Rx™ ICM (Abbott) is a minimally invasive CE-marked, FDA-approved cardiac monitor, implanted in a clinic setting for patients who experience unexplained symptoms, such as dizziness; palpitations, chest pain, syncope, shortness of breath, as well as for patients who are at risk for cardiac arrhythmias. Over 40,000 Confirm RX™ have been implanted and the device is in routine clinical use in the UK.

Here, we detail the protocol for a study in which patients with intermediate-low risk PAH, established on guideline-recommended dual oral therapy,²⁹ will be implanted with CardioMEMS and ICM devices. Following implantation, patients will enter a 2x2 crossover study in which PDEi will be replaced with sGCS (ERA + sGCS), or an IP receptor agonist will be added to PDEi and ERA (PDEi + ERA + IP receptor agonist). Data obtained from remote monitoring will be compared with that from established clinical investigations undertaken at baseline and maximal therapy on each drug. The crossover design of this study, which will incorporate structured up-titration of these drugs, is aimed at evaluating the capacity of implantable technology for early evaluation of the clinical efficacy of these drugs.

PHoenix

A crossover study is the logical study design to investigate intra-patient efficacy of these treatment options and increases the power to detect clinical efficacy. Additionally, the study will provide insight regarding the capacity of remote monitoring technology to facilitate trials that are not currently possible due to the requirement for repeated, hospital-based invasive/imaging procedures.

Methods

Study design

This open-label, phase 4, multicentre, randomised 2x2 crossover study (NCT05825417) in patients with PAH established on dual therapy (PDE5i/ ERA) will evaluate the effects via clinical investigations, patient-reported outcomes and remote cardiac monitoring of two therapeutic strategies – adding an oral drug targeting the prostacyclin pathway (selexipag; PDEi + ERA + IP receptor agonist) and switching of PDE5i to an sGCS (riociguat; ERA + sGCS). Using the 2x2 crossover trial design, patients will receive both therapies but the sequence will be randomly assigned with washout phases between therapies, and assessments of response to each therapy to be performed.³⁰ The study protocol was approved by the NHS Health Research Authority (IRAS PROJECT ID 325120, REC Reference 23/NE/0067). A tabulated summary of all visits and assessments is provided in **Supplementary Table 1**.

Objectives and endpoints

The main aims of this study will be to assess the individual difference in effect between treatment escalation with selexipag (PDEi + ERA + IP receptor agonist) or riociguat (riociguat; ERA + sGCS) on RV stroke volume (flow) as measured by cardiac MRI in patients with intermediate-low risk PAH, and to determine whether remote monitoring

PHoenix

devices can be used to provide an early assessment of clinical efficacy of drug therapies for PAH.

The primary endpoint will be change in RVSV (flow) measured by MRI from baseline to 12 weeks for each therapeutic strategy. Change in RVSV provides a robust, objective assessment of clinical efficacy and will represent a clinically meaningful change in physiology.³¹

Secondary endpoints for each therapeutic strategy include change from baseline to 12 weeks in haemodynamics (total peripheral resistance [TPR], mean pulmonary artery pressure [mPAP], cardiac output [CO], cardiac index, stroke volume [SV], heart rate [HR]), 6MWT, NTpro-BNP, MRI parameters (RVEF, right ventricular end systolic volume [RVESV], right ventricular end diastolic volume [RVEDV], RVSV (volume), left ventricular ejection fraction [LVEF], left ventricular end systolic volume [LVESV], left ventricular end diastolic volume [LVEDV], LSV flow), quality of life (EmPHasis-10), medication compliance (PHoenix PRO) and side effects, depression and anxiety symptoms (Generalized Anxiety Disorder-[GAD]-2/7 and Patient Health Questionnaire [PHQ]-2/9), WHO functional class, and activity levels as measured with a Garmin Venu2 smartwatch. A full list of outcome measures is provided in **Table 1**.

Established clinical study endpoint measures at maximal therapy will be compared to changes in remotely monitored parameters measured at 4 and 8 weeks to determine if the implanted devices can detect structured changes in the clinical therapy, thereby facilitating early assessment of clinical efficacy. Remote monitored parameters to be correlated with maximal therapy assessments, measured as absolute change from baseline and area under the curve to 4 and 8 weeks on each therapy, include haemodynamics (mPAP, CO, cardiac index, TPR, day HR, night HR, HR reserve), activity (minutes per day), 6MWT, and PRO.

PHoenix

Analysis will also be performed to determine if changes in established and remotely monitored parameters (primary and secondary endpoints) can detect individual patient-level therapy effects, thereby determining the utility of remote monitoring for personalised treatment plans.

Study population

The study aims to recruit 40 patients with PAH, established on PDE5i and ERA, through the UK National Pulmonary Hypertension Clinical Studies Network (UNIPHY) – a collaboration of UK centres commissioned for the treatment of PAH, providing access to all patients within the UK currently receiving targeted therapy for PAH (>5000).^{33,34} Suitable patients will be identified from existing patient lists by local teams and invited to screening via clinical and research teams.

Eligible patients meeting the inclusion and exclusion criteria (**Table 2**) will be established on PDE5i/ERA dual therapy and will meet NHS England's National Commissioning and ESC guideline criteria for initiation of IP receptor agonist or sGCS.^{3,10,11} While it is expected the majority of patients recruited will have intermediate-low risk PAH, patients with intermediate-high risk PAH who decline intravenous therapy will also be considered.

Device implantation

Eligible patients will be implanted using standard techniques with CardioMEMS and Confirm Rx ICM devices and remote monitoring data collected using regulatory-approved online portals.²⁸

PHoenix

Treatment

Patients will be randomised 1:1 to one of two treatment sequences (**Figure 1**), with comparisons to be made using patient-level data within the two treatment arms.

Randomisation will be done by authorised staff at study sites using a concealed randomisation system via the Zeesta electronic case report form (eCRF - www.zeesta.ai/) portal. A block randomisation stratified by site with a block size of four will be employed.

As per standard practice, the treatment schedules will include a minimum PDE5i washout period of 24–48 hours (depending on PDE5i) prior to initiation of riociguat;² in addition, riociguat and selexipag will be titrated according to established dose-adjustment schemes over a 6-week period to maximum doses of 2.5 mg three times per day, and 1600 µg twice daily, respectively as tolerated.

In brief, patients in Arm A will initiate treatment with selexipag for uptitration to maximal therapy. Prior to crossover, patients will undergo selexipag dose de-escalation and washout, followed by PDE5i washout. Patients will then initiate treatment with riociguat for uptitration to maximal therapy. Patients in Arm B will have an initial PDE5i washout period before commencing treatment with riociguat. This will be followed by de-escalation and washout, and initiation of treatment with PDE5i prior to crossover to selexipag treatment. In both arms the primary endpoint evaluation will be undertaken following a minimum intended duration of 5 weeks on maximal tolerated dose of each therapy. The dose escalation and de-escalation protocol are shown in **Supplementary Table 2**.

Clinical assessments

Patients will undergo clinical assessments at baseline before receiving study drug treatment, and at Week 12 and Week 27 of the treatment schedule (**Figure 1**); these will

PHoenix

include haemodynamics, 6MWT, MRI and NT-proBNP assessments.

MRI analysis will be provided by a study-appointed core lab using certified clinicians; scans will be de-identified and analysed in random order independent of patient and time point. Analysis of primary and secondary endpoints will be undertaken in a blinded manner by an independent statistical team in accordance with a pre-specified statistical analysis plan.

Remote monitoring

Physiological parameters to be monitored will include TPR, mPAP, CO, SV, and HR (**Table 1**). Patients will be given instructions on how to take readings at the time of implantation. In addition, remote detection of changes in physical activity levels will be measured by Garmin Venu2 smartwatch, and the 6-minute walk test (6MWT) performed at home.

Patient-reported outcomes

To date, no published randomised controlled trials in PAH have undertaken PAH-specific PRO instruments as secondary endpoints (**Figure 2**). The current study aims to understand patients' attitudes about PAH medications and the impact of the study medication on quality of life, as well as exploring attitudes about the use of remote technologies.

Quality of life outcomes will be assessed weekly using the validated EmPHasis-10 questionnaire.³⁵ Validated questionnaires will be used twice monthly to screen for anxiety (GAD-2)³⁶ and depression (PHQ-2) symptoms.³⁷

Patients will also be asked to record, on a weekly basis, any side effects of the study medications and to track dose-response changes that are observed. Data will be collected on

PHoenix

patients' attitudes towards their PAH medications and patient-reported medication compliance (PHoenix PRO questionnaire; **Supplementary Figure 1**). All participants will be invited to co-enrol in the COHORT-digital study,³⁸ which enables PRO reporting through a mobile application called Atom5™ (**Figure 3**). If participants decline to co-enrol for digital PRO reporting, data for these outcomes will be collected using a 10-item questionnaire via telephone communication into the eCRF.

Additionally, patients will also be asked to provide their insight to help understand attitudes regarding remote monitoring and clinical care and health outcomes at enrolment and study completion.

Safety

Adverse events (AEs) will be monitored over the duration of the study period; AEs that are definitely or possibly related to the device or the insertion procedure should be considered device-related (adverse device effect [ADE]).

Statistical analyses

Sample size calculation

A sample size was chosen to ensure adequate power to detect differences in the clinical efficacy of the two treatment approaches in population-level analyses and to have adequate power to evaluate the ability of implantable/remote technology to provide early evaluation of such clinical efficacy. For comparing the clinical efficacy of the two treatment approaches, we have used published RSVV data reporting a minimal clinically important difference of 12 mL and within-patient standard deviation (SD) of 16.5 mL.³⁹ The current study will be powered using a standardised effect (SE) of $12/16.5=0.73$. Assuming 1:1

PHoenix

randomisation of the participants to the two treatment sequences, 40 participants will provide 90% power in the population-level clinical efficacy analysis for a 5% two-sided type-I error-rate, with SE of 0.73. This is below the SE previously reported for the pulmonary vascular resistance (PVR; $SE=353.4/219.0=1.61$),⁴ and the RVEF ($SE=9.12/7.39=1.23$)²⁰ and comparable to that observed for the 6MWT ($SE=36.0/46.7=0.77$).⁷ Therefore, the study will be well powered for population-level analyses of these additional important outcomes.

The sample size of 40 also provides good power for assessing whether changes in remote physiological measures from baseline to 4 and 8 weeks (mPAP, CO, HR, and heart rhythm) are correlated with change in clinical measures from baseline to 12 weeks. The sample size of 40 patients provides 90% power, at a two-sided 5% type-I error-rate, for correlations greater than 0.5, which would represent those of clinical interest.

The study is not powered for formal mediation analysis, so this will be considered exploratory. No formal multiple testing correction will be applied.

Statistical analysis plan

All statistical analysis plans (SAPs) will be drafted early in the study and finalised prior to the analysis of unblinded data.

The primary clinical efficacy analysis will use a linear mixed effects model with the dependent variable being the change in RSVV (flow) from baseline to 12 weeks. “Baseline” and “12 weeks” refer to the time points within each treatment period. Each participant will contribute up to two observations if they complete both treatment periods. A random effect for each participant will be included together with the within-treatment period baseline RSVV (flow) measurement, a fixed period effect, and treatment (selexipag or riociguat) allocated during the treatment period. This model will be used to estimate the mean

PHoenix

difference between the two treatment approaches (ERA + sGCS and PDEi + ERA + IP receptor agonist), together with 95% confidence interval and a p-value using a Wald test.

Similar methods will be applied to the analysis of secondary efficacy outcomes.

Treatment effect heterogeneity between subgroups will be assessed by including treatment-by-subgroup interaction terms in regression models. Main analyses will use complete data only, but multiple imputation will be used for missing data in sensitivity analyses. No adjustments will be made for multiple statistical testing. All efficacy analyses will follow the intention to treat principle (i.e., analysis according to randomised treatment, regardless of treatment compliance). Safety data (adverse events and side effects) will be summarised in relation to treatment being received at the onset of the event, and the study period (pre-treatment period 1, treatment period 1, washout period, treatment period 2, post-treatment period 2); no formal statistical comparisons will be applied.

To analyse whether changes in RSVV (flow) may be explained by remotely monitored physiological parameters, we will test whether there is a significant correlation between change between baseline and Week 4/Week 8 physiological parameters and change between baseline and Week 12 RSVV (flow) outcome. We will also adopt a mediation analysis approach to investigate what proportion of the change between baseline and Week 12 RSVV (flow) is explained by the change between baseline and Week 4/Week 8 physiological parameters using the mediation package in R. Secondary endpoints will be analysed using appropriate regression models.

Discussion

Patients with PAH receiving dual combination treatment (PDE5i + ERA) who are stratified as being at intermediate-low risk are recommended to intensify therapy via addition

PHoenix

of the IP receptor agonist, selexipag, or to switch from a PDE5i to the sGCS, riociguat.^{10,11,29}

There is clinical equipoise between triple therapy with selexipag + PDE5i + ERA and dual therapy with riociguat + ERA. Conducting head-to-head clinical trials to compare treatment strategies in patients with PAH is challenging due to the current necessity for repeated, hospital-based invasive/imaging procedures to evaluate treatment efficacy. Remote haemodynamic and cardiac monitoring may provide a means for early, minimally invasive evaluation of clinical efficacy and early identification of clinical worsening in patients with PAH, which may facilitate study designs evaluating dose-response, time-to-effect and head-to-head comparison. This study is designed to assess the individualised effect of selexipag and riociguat on RV stroke volume as measured by cardiac MRI, and to determine whether remote monitoring devices can be used to provide an early assessment of clinical efficacy of drug therapies for PAH. This hybrid drug-device regulatory approved design represents the first evaluation of an sGCS and IP agonist.

This blinded analysis of MRI objective measures provides an efficient, robust and effective clinical study structure. As the primary endpoint is objective with blinded analysis, patients and clinicians will not be blinded to the sequence of drug allocation and up-titration.

In this study, data will be relayed daily from regulatory approved, minimally invasive monitors to care teams through secure online clinical portals, with the aim of facilitating early, individual-level, remote evaluation of treatment effects. This study will offer the potential to build on existing evidence showing that remotely monitored parameters may be used at diagnosis to categorise patients with PAH as low, intermediate, or high risk.²⁴ In addition to offering the potential for early evaluation of therapies, the use of remotely monitored outcomes may provide a broader picture of the effects of treatment on patients' daily functioning.²⁵ Remote patient monitoring may also facilitate more patient-centric research, and improve study recruitment and retention, which are key issues for research into

PHoenix

a rare disease such as PAH.^{21,25} Additionally, patients with PAH are typically prescribed combination therapies, which can make it challenging to power trials to demonstrate the effectiveness of novel therapies.^{20,21}

In addition to capturing data on established physiological and biochemical markers of clinical risk, this study will provide valuable insight into patient-reported quality of life and mental health outcomes, as well as exploring side effects experienced during therapeutic up-titration and withdrawal of therapy.

PHoenix

Declarations

Dr Frances Varian: MRC clinical research fellow, conference funding from Janssen and Janssen

Dr Jennifer Dick: none declared

Mr Christian Battersby: none declared

Mr Stefan Roman: none declared

Miss Jenna Ablott: none declared

Dr Lisa Watson: none declared

Mrs Sarah Bizmahfooz: none declared

Dr Hamza Zafar: none declared

Dr Gerry Colgan: no direct conflicts, has undertaken consultancy work & honoraria for Janssen Ltd, Bayer Ltd, MSD. Received research funding from Janssen Ltd.

Dr John Cannon: support to attend conferences from Janssen and been paid for advisory boards by Janssen and Ferrer.

Jay Suntharalingam: none declared

Dr Jim Lordan: none declared

Professor Luke Howard: I have received honoraria for advisory boards, steering committees and speaking from Janssen. My department has received research funding support from Janssen. I have received personal support for travel, accommodation and registration at international meetings. I have received honoraria for advisory boards and speaking from MSD. I have received honoraria for advisory boards from Endotronix.

Colm McCabe: none declared

Dr John Wort: I have received honoraria from Janssen, MSD, Ferrer and Acceleron, research grants from Janssen and Ferrer and travel and accommodation grants from Janssen

Laura Price: none declared

Dr Colin Church: none declared

Dr Neil Hamilton: Honoraria from MSD and Janssen, travel and accommodation grants from Janssen, participation on advisory boards for Bayer, MSD, Janssen and Vifor and is a board member on the NHS Specialist respiratory clinical reference group. Iain Armstrong

Dr Abdul Hameed: none declared, <https://orcid.org/0000-0002-2128-2081>

Dr Judith Hurdman: none declared

Dr Charlie Elliot: none declared

Prof Robin Condliffe: No COI. Received honoraria for speaking and advisory boards from Janssen and MS

Prof Martin Wilkins: support from NIHR for clinical research facility and biomedical research centre infrastructure support BHF centre support (RE/18/4/34215), consulting fees for MorphogenIX, Janssen and Janssen, Kinaset, Chiesi, Aerami, BenevolentAI, Novartis, and VIVS, participation on

PHoenix

data safety monitoring board for Acceleron and GSK,

Associate Professor Alastair Webb: none declared

Dr David Adlam: none declared

Professor Ray L Benza: steering and adjudication committees ABBOTT

Professor Kazem Rahimi: receives grants from the Oxford Martin School and the British Heart Foundation. KR is an associate editor of Heart and specialty editor of PLOS Medicine. KR is a co-founder of Zeesta and sits on the advisory board of Medtronic

Dr Moha Shojaei: none declared

Dr Nan Lin: none declared

Prof James Wason: none declared

Dr Alasdair McIntosh: none declared

Prof Alex McConnachie: none declared

Dr Jennifer Middleton: none declared

Dr Roger Thompson: I have received honoraria, travel support and grant funding from Janssen

Prof David Kiely: Support and grants received from NIHR Sheffield Biomedical Research Centre, Janssen Pharmaceuticals; additional grants from Ferrer; consulting fees, honoraria payments and supports for attending meetings received from Janssen Pharmaceuticals, Ferrer, Altavant, MSD and united Therapeutics, participants on advisory boards with Janssen and MSD; members of clinical reference group for specialist respiratory medicine (NHS England) and lead of UK national audit of pulmonary hypertension.

Dr Mark Toshner: Funding from NIHR Cambridge BRC, NIHR HTA; consulting fees from MorphogenIX and Jansen, participation on data safety monitoring board/advisory board with ComCov and FluCov.

Dr Alex Rothman: Research funding: Wellcome Trust Clinical Research Career Development Fellowship (206632/Z/17/Z), Medical Research Council (UK) Experimental Medicine Award (MR/W026279/1), NIHR Biomedical Research Center Sheffield, Contribution in kind: Medtronic, Abbott, Endotronix, Novartis, Janssen. Research support and consulting: NXT Biomedical, Endotronix, SoniVie, Neptune, Gradient. MT: Research funding: NIHR Biomedical Research Center Cambridge, NIHR HTA. Personal support: GCK and Jansen. DSMB: ComCov, FluCov. PDM: personal support: Abbott.

Conflicting interests

The author(s) declare that there is no conflict of interest.

PHoenix

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:

The study is funded by an MRC Experimental Medicine Project award MR/W026279/1.

Devices are provided by Abbot. Wellcome Trust Clinical Research Career Development

Fellowship (AR: 206632/Z/17/Z; AS: 205188/Z/16/Z, PDM: 214567/Z/18/Z), BHF

Intermediate Fellowship (AART: FS/18/13/33281), National Institute for Health Research

(JMSW: NIHR301614). AR is grateful to Richard Hughes, whose generous philanthropic support has helped to make this work possible.

Ethical approval

IRAS project ID: 325120

REC reference: 23/NE/0067

Contributorship

The study was designed by AR with representatives from the UK Pulmonary Hypertension Network (CC, GC, RC, LH, DK, JL, AR, JS, MT and SJW), the clinical research fellow (FV) and the clinical trial manager (JD). All the authors contributed to the development of the manuscript and approved the final version of the article.

Acknowledgements

The authors thank Aisling O’Keeffe, PhD, and Allison Kirsop, PhD, of Scientific Writers Ltd., for providing medical writing support.

References

1. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. *BMJ*. 2018;360:j5492.
2. Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. *Lancet Respir Med*. 2021;9(6):573-584.
3. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43(38):3618-3731.
4. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *Eur Respir J*. 2012;40(4):874-880.
5. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2015;373(26):2522-2533.
6. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. *Eur Respir J*. 2010;36(4):792-799.
7. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2013;369(4):330-340.
8. Weatherald J, Boucly A, Chemla D, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. *Circulation*. 2018;137(7):693-704.
9. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. *N Engl J Med*. 2015;373(9):834-844.
10. NHS England. Clinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (adults). Published December 2018. Available at: <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2018/12/Selexipag-for-treating-pulmonary-arterial-hypertension-adults.pdf>. Accessed June 2023.
11. NHS England. Clinical Commissioning Policy: Riociguat for pulmonary arterial hypertension. Published February 2017. Available at: <https://www.england.nhs.uk/wp-content/uploads/2017/06/ccp-riociguat-pulmonary-arterial-hypertension.pdf>. Accessed June 2023.
12. Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. *J Am Coll Cardiol*. 2021;78(14):1393-1403.
13. Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. *Lancet Respir Med*. 2016;4(5):361-371.
14. Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). *Eur Respir J*. 2015;45(5):1303-1313.
15. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation*. 2009;119(22):2894-2903.
16. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2005;353(20):2148-2157.
17. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary

PHoenix

- arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*. 2008;117(23):3010-3019.
18. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet*. 2008;371(9630):2093-2100.
 19. Kiely DG, Channick R, Flores D, et al. Comparison of standardized treatment effect sizes for invasive and non-invasive endpoints in pulmonary arterial hypertension: Insights from the REPAIR study. *J Am Coll Cardiol* 2021;77(18_Supplement_1):1672-1672.
 20. Swift AJ, Wilson F, Cogliano M, et al. Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. *Thorax*. 2021;76(10):1032-1035.
 21. Weatherald J, Boucly A, Peters A, et al. The evolving landscape of pulmonary arterial hypertension clinical trials. *Lancet*. 2022;400(10366):1884-1898.
 22. NHS England. Commissioning Policy: Targeted therapies for use in pulmonary hypertension in adults. Published July 2015. Available at: <https://www.england.nhs.uk/wp-content/uploads/2018/07/Targeted-therapies-for-use-in-pulmonary-hypertension-in-adults.pdf>. Accessed June 2023.
 23. Middleton JT, Binmahfooz S, Zafar H, et al. Abstract 13553: Remote monitoring of the haemodynamic response to clinically indicated therapeutic escalation and clinical worsening events in patients with pulmonary arterial hypertension. *Circulation*. 2022;146(Suppl_1):A13553-A13553.
 24. Middleton JT, Binmahfooz S, Zafar H, et al. Abstract 13527: The development of a remote pulmonary arterial hypertension risk score utilising remote monitoring technology to monitor parameters associated with mortality in pulmonary arterial hypertension. *Circulation*. 2022;146(Suppl_1):A13527-A13527.
 25. Clinical Trials Transformation Initiative (CTTI). Digital Health Trials: Developing novel endpoints generated by digital health technology for use in clinical trials. Available at: <https://ctti-clinicaltrials.org/wp-content/uploads/2022/03/CTTI-Digital-Health-Trials-Novel-Endpoint-Acceptance-Recommendations.pdf>. Accessed June 2023.
 26. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *Lancet*. 2016;387(10017):453-461.
 27. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. *Lancet*. 2021;398(10304):991-1001.
 28. Middleton JT, Binmahfooz S, Zafar H, et al. Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension. *medRxiv*. 2023:2023.2004.2027.23289153.
 29. Rosenkranz S, Delcroix M, Giannakoulas G, Hoeper MM, Kovacs G, Humbert M. The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2023;44(10):792-793.
 30. Kane PB, Bittlinger M, Kimmelman J. Individualized therapy trials: navigating patient care, research goals and ethics. *Nat Med*. 2021;27(10):1679-1686.
 31. Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. *JACC Cardiovasc Imaging*. 2021;14(5):931-942.
 32. Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk

PHoenix

- assessment model for pulmonary arterial hypertension. *Eur Respir J.* 2022;60(1).
33. Pulmonary Hypertension Association UK (PHA UK). Pulmonary hypertension specialist centres. Available at: <https://www.phauk.org/treatment-for-pulmonary-hypertension/pulmonary-hypertension-specialist-centres/>. Accessed July 2023.
 34. NHS Digital. National Pulmonary Hypertension Audit, 13th Annual Report. Published 19 January 2023. Available at: <https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/13th-annual-report>. Accessed June 2023.
 35. Lewis RA, Armstrong I, Bergbaum C, et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. *Eur Respir J.* 2021;57(2).
 36. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med.* 2007;146(5):317-325.
 37. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care.* 2003;41(11):1284-1292.
 38. National Cohort Study of Idiopathic and Heritable PAH. Available at: <https://www.ipahcohort.com/>. Accessed July 2023.
 39. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, et al. Clinically significant change in stroke volume in pulmonary hypertension. *Chest.* 2011;139(5):1003-1009.

PHoenix

Tables & Figures

Table 1. Outcome measures

	Hospital-based measures	Remotely monitored measures
Primary outcomes	Change in RSVV (flow) measured by MRI	
Secondary outcomes	<p>Haemodynamics:</p> <ul style="list-style-type: none"> • TPR • mPAP • CO • Cardiac index • SV • HR <p>MRI parameters:</p> <ul style="list-style-type: none"> • RVEF • RVESV • RVEDV • RSVV (volume), • LVEF • LVESV • LVEDV • LSVV flow <p>Other parameters:</p>	<p>Confirm Rx:</p> <ul style="list-style-type: none"> • HR • HR variability • Cardiac rhythm • Thoracic impedance • Respiratory rate <p>CardioMEMS:</p> <ul style="list-style-type: none"> • mPAP • CO • SV <p>Smartwatch (Garmin Venu2):</p> <ul style="list-style-type: none"> • Physical activity • Physiological measurements (TPR, mPAP, CO, cardiac index, SV, and HR)

PHoenix

	<ul style="list-style-type: none"> • 6MWT • NTpro-BNP • WHO functional class • Quality of life (EmPHasis-10) • Depression and anxiety symptoms (GAD-2/7 and PHQ-2/9) • Medication compliance (PHoenix PRO questionnaire) • Side effects 	<p>Phone apps:</p> <ul style="list-style-type: none"> • PRO (Phoenix remote questionnaire) • Medication compliance (myCardioMems app) <p>6MWT</p>
--	--	---

6MWT, 6-minute walk test; CO, cardiac output; HR, heart rate; GAD, Generalized Anxiety Disorder; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; mPAP, mean pulmonary artery pressure; PHQ, Patient Health Questionnaire; PRO, patient-reported outcome; RVEDV, right ventricular end diastolic volume; RVESV, right ventricular end systolic volume; RVSV, right ventricular stroke volume; SV, stroke volume; TPR, total peripheral resistance.

Table 2. Summary of eligibility criteria

<p>Inclusion criteria:</p> <ol style="list-style-type: none">1. Able to provide informed consent2. Age 18–80 years3. PAH which is idiopathic, heritable or associated with drugs, toxins or connective tissue disease4. Stable PAH therapeutic regime comprising any combination of ERA and PDE5i for at least 1 month prior to screening (unless unable to tolerate therapy)5. WHO functional class III6. Resting mPAP ≥ 20 mmHg, pulmonary capillary wedge pressure ≤ 15 mmHg, pulmonary vascular resistance ≥ 2 Wood Units measured by right heart catheterisation at time of diagnosis7. 6MWT > 50 minutes at entry8. eGFR > 30 mL/min/1.73 m² at entry9. Inadequate treatment response (clinically determined)
<p>Exclusion criteria:</p> <ol style="list-style-type: none">1. Unable to provide informed consent2. Pregnancy3. Unprovoked pulmonary embolism (at any time)4. Acute infection at time of screening (rescreening is permitted)5. PAH due to human immunodeficiency virus, portal hypertension, schistosomiasis, congenital heart disease6. Pulmonary hypertension due to left heart, lung, thromboembolic or unclear/multifactorial

PHoenix

disease (Group II-V)

7. Unable to tolerate aspirin or P2Y12 inhibitor
8. Hypersensitivity to selexipag or riociguat
9. Clinically significant renal disease (eGFR \leq 30 ml/min/1.73m²)
10. Anaemia (haemoglobin <10 g/dl)
11. Left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following: aortic or mitral valve disease greater than mild aortic insufficiency; mild aortic stenosis; mild mitral stenosis; or moderate mitral regurgitation


eGFR, estimated glomerular filtration rate; ERA, endothelin-1 receptor antagonist; mPAP,

mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PDE5i,

phosphodiesterase-5 inhibitor.

PHoenix

Figure 1. Dose escalation and de-escalation protocol




Created with BioRender.com

Bd, twice daily; CMR, cardiac magnetic resonance imaging; ERA, endothelin receptor antagonist; OPA, oral IP-receptor agonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase type-5 inhibitor; sGCS, soluble guanylate-cyclase stimulator; tds, three times daily; WHO FC, World Health Organization Functional Class.

PHoenix

Figure 2. Primary outcomes in landmark PAH randomised controlled trials with patient-reported outcomes included as secondary endpoints




DFI, dyspnoea fatigue index; EQ-5D, EuroQoL five-dimension; MLWH, Minnesota Living with Heart Failure questionnaire; M&M, morbidity and mortality; PAH, pulmonary arterial hypertension; PRO, patient-reported outcome; PVR, pulmonary vascular resistance; SF-36, short-form 36;

Exercise endpoint inclusive of 6-minute walk distance and actigraphy;

^aLiving with pulmonary hypertension (LPH) questionnaire was undertaken in PATENT-1; however, this was considered exploratory.

PHoenix

Figure 3. Patient-reported outcomes in the PHoenix study



Created with BioRender.com

A, Arm A = riociguat/selexipag and B, Arm B = selexipag/riociguat
GAD, Generalized Anxiety Disorder questionnaire; PHQ, Patient Health Questionnaire.

PHoenix

Supplementary appendix:

Supplementary Table 1. Schedule of events

Assessments at screening and baseline need only be completed once if no change in clinical condition between visits. Dosing schedule follows on next page.

Arm B (n = 20)	Pre-treatment*	Baseline readings and Implantation	Wash out PDE and up titrate sGCS	End of sGCS up-titration (max tolerated)	De-escalate sGCS	Washout. sGCS, start PDE	Start & up-titrate OPA	End of up-titration OPA	
Visit number assigned/time (weeks)	Before Week 0 (screening)	Week 0 (baseline)	Week 1-11 as required	Week 12	Weeks 13-14	Week 15	Week 16-26 as required	Week 27	Clinical need (any time)
Visit type	Assess 1 (screening)	Assess 2 (baseline)	TV - SoC*	Assess 3	TV - SoC*	Assess 4	TV - SoC*	Assess 5	Unscheduled visit
Location	Clinic	Clinic	☎	Clinic	☎	Clinic	☎	Clinic	Clinic
Visit Window (days)	0-45 days	± 5 days	± 5 days	± 5 days	± 5 days	± 5 days	± 5 days	± 5 days	n/a
Inclusion/Exclusion criteria	X	-	-	-	-	-	-	-	-
PHoenix informed consent form	X	-	-	-	-	-	-	-	-
National Cohort Study of Idiopathic and Heritable PAH consent form (optional)	X	-	-	-	-	-	-	-	-
Demographics	X	-	-	-	-	-	-	-	-
Medical and medication history	X	-	-	-	-	-	-	-	-
Physical examination	-	X	-	X	-	X	-	X	X
Drug administration and results of titration	-	PDE/ERA <i>refer table overleaf & table 9</i>	ERA/sGCS <i>refer table overleaf</i>	ERA/sGCS <i>refer table overleaf</i>	ERA/sGCS <i>refer table overleaf</i>	PDE/ERA <i>refer table overleaf</i>	PDE/ERA/OPA <i>refer table overleaf</i>	PDE/ERA/OPA <i>refer table overleaf</i>	X
Concomitant medications	-	X	X	X	X	X	X	X	X
Vital signs	-	X	-	X	-	X	-	X	X
WHO Functional Class	X	X	X	X	X	X	X	X	X
6MWT	-	X	-	X	-	X	-	X	X
Borg Dyspnoea Index	-	X	-	X	-	X	-	X	X
RHC and device implantation	-	X [†]	-	-	-	-	-	-	-
CardioMEMS™ and ConfirmRx™ (or equivalent) data reading	-	Participant led - readings taken daily throughout study***							
Haematology blood tests	-	X	-	X	-	X	-	X	X
Clinical chemistry tests	-	X	-	X	-	X	-	X	X
Pregnancy test (Urine)	-	X	-	-	-	-	-	-	-
Research blood samples	-	X	-	X	-	X	-	X	X
Electrocardiogram (ECG)	-	X	-	-	-	-	-	-	X
MRI scan	-	X	-	X	-	X	-	X	-
Report adverse events, if any	-	X	X	X	X	X	X	X	X
Remote 6MWT**	-	-	X	-	X	-	X	-	-
PRO (EmPHasis-10, GAD-2/7, PHQ-2/9, PHoenix PRO, side effects)	-	Participant led - PROs to be completed weekly throughout study***							
PHoenix-PRO-Remote	-	X	-	-	-	-	-	X	-

AEs, adverse events; ERA, endothelin receptor antagonist; GAD, generalised anxiety disorder questionnaire; MRI, magnetic resonance imaging; OPA, oral prostaglandin receptor agonist; PDE, phosphodiesterase type-5 inhibitor; PHQ, patient health questionnaire; PRO, patient-reported outcomes; RHC, right heart catheterisation; SoC, standard of care; sGCS, soluble guanylate-cyclase stimulator; TV, telephone visit; 6MWT, six-minute walk distance; WHO, World Health Organisation.

*Weekly phone calls will be completed as part of standard care for drug titrations. Standard activities for these calls are documented in these columns. None of these are additional for research, but relevant findings (i.e., AEs) will be reported to the study team for

PHoenix

documentation. A participant may not reach the maximum dose, but all calls will be required to assess symptoms and review opportunities to continue to increase the dose and address and ongoing side effects.

**Remote 6MWTs will be completed as part of the UK H/IPAH cohort study where participants are co-enrolled or via an alternative approved application; this is participant led.

***Central team to monitor compliance of pressure readings and follow up with local teams or participants if necessary. Local teams to check compliance with PROs at study visits.

[§]If not already in place.

PHoenix

Supplementary Table 2. Dose escalation and de-escalation protocol for (A) Arm A and (B)

Arm B

(A)

Arm A (selexipag/riociguat) Dosing Schedule					
Week	Drug	Dose	Therapy	Notes on titration	WHOFC
Screening			PDE/ERA		
Implantation			PDE/ERA		
1	Initiate OPA	200 mcg bd	PDE/ERA/OPA		
2		400 mcg bd	PDE/ERA/OPA		
3		600 mcg bd	PDE/ERA/OPA		
4		800 mcg bd	PDE/ERA/OPA		
5		1000 mcg bd	PDE/ERA/OPA		
6		1200 mcg bd	PDE/ERA/OPA		
7		1400 mcg bd	PDE/ERA/OPA		
8		1600 mcg bd	PDE/ERA/OPA		
9		1600 mcg bd	PDE/ERA/OPA		
10		1600 mcg bd	PDE/ERA/OPA		
11		1600 mcg bd	PDE/ERA/OPA		
12		1600 mcg bd	PDE/ERA/OPA		
13	Reduce OPA	1200 mcg bd 800 mcg bd 600 mcg bd	PDE/ERA/OPA		
14		400 mcg bd 200 mcg bd	PDE/ERA/OPA		
15			PDE/ERA		
16	Switch PDE	Wash out PDE	ERA		
17	Initiate sGCS	1 mg tds	ERA/sGCS		
18		1 mg tds	ERA/sGCS		
19		1.5 mg tds	ERA/sGCS		
20		1.5 mg tds	ERA/sGCS		
21		2.0 mg tds	ERA/sGCS		
22		2.0 mg tds	ERA/sGCS		
23		2.5 mg tds	ERA/sGCS		
24		2.5 mg tds	ERA/sGCS		
25		2.5 mg tds	ERA/sGCS		
26		2.5 mg tds	ERA/sGCS		
27		2.5 mg tds	ERA/sGCS		
Observation					

PHoenix

(B)

Arm B (riociguat/selexipag) Dosing Schedule					
Week	Drug	Dose	Therapy	Notes on titration	WHO FC
			PDE/ERA		
Baseline			PDE/ERA		
1	Switch PDE	Wash out PDE	ERA		
2	Initiate sGCS	1 mg tds	ERA/sGCS		
3		1 mg tds	ERA/sGCS		
4		1.5 mg tds	ERA/sGCS		
5		1.5 mg tds	ERA/sGCS		
6		2.0 mg tds	ERA/sGCS		
7		2.0 mg tds	ERA/sGCS		
8		2.5 mg tds	ERA/sGCS		
9		2.5 mg tds	ERA/sGCS		
10		2.5 mg tds	ERA/sGCS		
11		2.5 mg tds	ERA/sGCS		
12		2.5 mg tds	ERA/sGCS		
13	Reduce sGCS	2.0 mg tds 1.5 mg tds	ERA/sGCS		
14		1.0 mg tds Wash out	ERA/sGCS ERA		
15	Initiate PDE		PDE/ERA		
16	Initiate OPA	200 mcg bd	PDE/ERA/OPA		
17		400 mcg bd	PDE/ERA/OPA		
18		600 mcg bd	PDE/ERA/OPA		
19		800 mcg bd	PDE/ERA/OPA		
20		1000 mcg bd	PDE/ERA/OPA		
21		1200 mcg bd	PDE/ERA/OPA		
22		1400 mcg bd	PDE/ERA/OPA		
23		1600 mcg bd	PDE/ERA/OPA		
24		1600 mcg bd	PDE/ERA/OPA		
25		1600 mcg bd	PDE/ERA/OPA		
26		1600 mcg bd	PDE/ERA/OPA		
27		1600 mcg bd	PDE/ERA/OPA		
Observation					

Bd, twice daily; ERA, endothelin receptor antagonist; OPA, oral prostacyclin receptor agonist; PDE, phosphodiesterase type-5 inhibitor; sGCS, soluble guanylate-cyclase stimulator; tds, three times daily.

PHoenix

Supplementary Figure 1. Phoenix PRO questionnaire

	Experience of taking PH medicines	0	1	2	3	4	5	
P	I do not understand why these medications were Prescribed							I fully understand why these medications were Prescribed
H	My medications don't Help my symptoms							My medications definitely Help my symptoms
O	None of my PH medications are important							All my PH medications are impOrtant
E	I frequently alter medications myself to suit my routinE							I never alter medications myself to suit my routinE
N	The Number of medications I am prescribed concerns me							The number of medications I am prescribed does not concern me
I	If I feel well, I prefer not to take my medication							Even if I feel well, I always take my medication
X	I have eX perienced side effects that have stopped me from taking my medication before discussing these with a clinician							I have not experienced side effects significant enough to stop medication without discussing with a clinician first
P	Taking medications daily is a Problem for me							Taking medications daily is not a Problem for me
R	I have difficulty Remembering to take medications every day							I have no difficulty remembering to take medications every day
O	There are times I Omit or forget my medication e.g., on holiday							I never forget or omit my PH medications, even if away from home

PH, pulmonary hypertension.

Schematic of individualised therapy in 2x2 crossover trial

